Magellan Health (MGLN) Expected to Post Quarterly Sales of $1.83 Billion
Wall Street analysts expect that Magellan Health (NASDAQ:MGLN) will announce sales of $1.83 billion for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Magellan Health’s earnings, with the lowest sales estimate coming in at $1.79 billion and the highest estimate coming in at $1.86 billion. Magellan Health reported sales of $1.31 billion in the same quarter last year, which would suggest a positive year over year growth rate of 39.7%. The company is expected to announce its next quarterly earnings results before the market opens on Thursday, April 26th.
According to Zacks, analysts expect that Magellan Health will report full-year sales of $7.66 billion for the current financial year, with estimates ranging from $7.61 billion to $7.71 billion. For the next year, analysts anticipate that the business will report sales of $8.19 billion per share, with estimates ranging from $8.06 billion to $8.30 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Magellan Health.
Magellan Health (NASDAQ:MGLN) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.26. Magellan Health had a net margin of 1.89% and a return on equity of 10.86%. The firm had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.62 billion. During the same quarter in the previous year, the business posted $1.80 EPS. The firm’s revenue was up 34.1% compared to the same quarter last year.
In other news, CEO Barry M. Smith sold 13,375 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $99.20, for a total value of $1,326,800.00. Following the sale, the chief executive officer now owns 42,807 shares in the company, valued at approximately $4,246,454.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Mostafa Kamal sold 15,428 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $99.04, for a total transaction of $1,527,989.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,428 shares of company stock worth $7,858,688. Company insiders own 4.60% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Gotham Asset Management LLC bought a new stake in shares of Magellan Health during the 4th quarter valued at about $201,000. Shelton Capital Management bought a new stake in shares of Magellan Health during the 4th quarter valued at about $205,000. Xact Kapitalforvaltning AB bought a new stake in shares of Magellan Health during the 4th quarter valued at about $275,000. CIBC Asset Management Inc bought a new stake in shares of Magellan Health during the 4th quarter valued at about $291,000. Finally, Meadow Creek Investment Management LLC grew its position in shares of Magellan Health by 20.8% during the 4th quarter. Meadow Creek Investment Management LLC now owns 3,416 shares of the company’s stock valued at $330,000 after buying an additional 588 shares during the last quarter. 96.12% of the stock is owned by institutional investors and hedge funds.
Shares of MGLN stock opened at $108.80 on Tuesday. The firm has a market capitalization of $2,670.46, a price-to-earnings ratio of 19.78, a PEG ratio of 1.14 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.58. Magellan Health has a 12 month low of $67.20 and a 12 month high of $111.10.
Magellan Health Company Profile
Magellan Health, Inc provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.